What We Do       Leadership       Therapeutic Areas       Partnering       News       Contact

Board of Directors

Stig Pedersen is the Executive Chairman of moksha8 and an active investor and Board Member in many companies within the health, medical and biotechnology industry in Europe and North America. He also serves as an Advisor to the Lundbeck Foundation.

He joined Lundbeck in 1992 where he held a number of positions. He served as member of the Executive Board and an Executive Vice President of Commercial Operations from 2003 to 2011. From 2005 to 2011 he was also Chief Commercial Officer and responsible for Lundbeck´s global sales and marketing activities. From 1992 to 1998 he served as Director of Business Development, Director of Corporate Affairs, Managing Director of Lundbeck’s subsidiary in the Netherlands, respectively. As Senior Vice President, Corporate Affairs, from 1998, he was responsible for the 3 product deals, transforming

Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Mr. Pedersen took over Operations in the America’s, Asia and Africa.

Mr. Pedersen served as an Economist at Dansk Shell A/S from 1985 to 1986, and joined Ciba-Geigy in Denmark 1986-1989, as respectively, Market Manager, Project Manager and Member of the Divisional Management. He was appointed Assistant Region Head in Basel, Switzerland, at Ciba-Geigy AG in 1990.

He serves as the Chairman of the Board of Directors in Transmedica A/S, Microlytic ApS, Chemometec A/S and Nuevolution A/S. He is Member of the Board of Directors of MSI

Methylation Sciences Inc in Vancouver, Canada and of Index Pharmaceuticals AB in Stockholm, Sweden. Previously, he has served as Chairman of the Board of Directors in Tytex A/S, Ikast, Denmark, Vernal AG, Basle, Switzerland, and R5 A/S, Copenhagen, Denmark.

 

Stig Pedersen

Executive Chairman

 

Daniel Turner III

Board Member

 

Pascal Forget

Board Member

 

Arthur Higgins

Board Member

 

Mariano Garcia-Valiño

Board Member

 

Joel Barlan

Chief Executive Officer

 


Management Team

 

COPYRIGHT © 2006-2019 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.

 

PRIVACY POLICY | LEGAL DISCLAIMER | LINKEDIN | ENGLISH | PORTUGUESE

Board of Directors

Stig Pedersen is the Executive Chairman of moksha8 and an active investor and Board Member in many companies within the health, medical and biotechnology industry in Europe and North America. He also serves as an Advisor to the Lundbeck Foundation.

 

He joined Lundbeck in 1992 where he held a number of positions. He served as member of the Executive Board and an Executive Vice President of Commercial Operations from 2003 to 2011. From 2005 to 2011 he was also Chief Commercial Officer and responsible for Lundbeck´s global sales and marketing activities. From 1992 to 1998 he served as Director of Business Development, Director of Corporate Affairs, Managing Director of Lundbeck’s subsidiary in the Netherlands, respectively.

 

As Senior Vice President, Corporate Affairs, from 1998, he was responsible for the 3 product deals, transforming Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Mr. Pedersen took over Operations in the America’s, Asia and Africa.

 

Mr. Pedersen served as an Economist at Dansk Shell A/S from 1985 to 1986, and joined Ciba-Geigy in Denmark 1986-1989, as respectively, Market Manager, Project Manager and Member of the Divisional Management. He was appointed Assistant Region Head in Basel, Switzerland, at Ciba-Geigy AG in 1990.

 

He serves as the Chairman of the Board of Directors in Transmedica A/S, Microlytic ApS, Chemometec A/S and Nuevolution A/S. He is Member of the Board of Directors of MSI

Methylation Sciences Inc in Vancouver, Canada and of Index Pharmaceuticals AB in Stockholm, Sweden. Previously, he has served as Chairman of the Board of Directors in Tytex A/S, Ikast, Denmark, Vernal AG, Basle, Switzerland, and R5 A/S, Copenhagen, Denmark.

 

Stig Pedersen

Executive Chairman

Mr. Turner has 30 years of experience as an entrepreneur, operating manager and venture capitalist. In 1993, he founded a private investment company called Montreux Equity Partner where he is the Managing Director and General Partner.

 

He has been a member and Chairman of GC Aesthetics and he also serves on the Board of Directors of multiple companies including Epirus Biopharmaceuticals, Inc., Glaukos Corporation, Orexigen Therapeutics, Inc., Renal CarePartners, Inc., Transcept Pharmaceuticals, Inc. and Tobira Therapeutics, Inc. Mr. Turner holds a bachelor’s degree from California State University, Sacramento.

 

Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Previously, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals in 1997.

 

Previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Board of Trustees at Woodside Priory School and a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.

 

He started his career with Price Waterhouse in the high technology group.

 

Daniel Turner III

Board Member

Pascal Forget is a Senior Executive with 34 Years of experience as President, Managing Director and Area Manager in the pharmaceutical and agro-veterinarian industries, working for leading groups such as Schering Plough, Hoescht Roussel, Roussel Uclaf and Grupo Farma.

For the last 14 years, Mr. Forget has been the CEO of a highly successful international pharmaceutical group with full LATAM coverage.

 

With solid expertise in M&A and joint ventures within the Pharma industry and international experience as an operational and global business manager in Latin and Central America and Europe, Mr. Forget is a valuable addition to moksha8’s BoD.

 

Mr. Forget holds a CPA Degree and an MBA degree from Ottawa University.

Pascal Forget

Board Member

Mr. Higgins serves as President and Chief Executive Officer and Director of Depomed since March 2017. He is a highly respected executive with over 35 years’ experience in the pharmaceutical and healthcare industry. He has extensive leadership experience in the global healthcare market and has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area.

He served as a Senior Advisor to Blackstone Healthcare Partners where he focused on product-based healthcare acquisitions.

 

Before Blackstone, he served as Chairman of the Bayer HealthCare Executive Committee in July 2004 and Chairman of the Board of Management of Bayer HealthCare AG in January 2006. During his tenure at Bayer, Mr. Higgins led the restructuring and strengthening of Bayer HealthCare including the acquisition and integration of Schering AG and the over-the-counter medicines business of Roche.

 

Prior to joining Bayer, he was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, N.J. Higgins also spent 14 years with Abbott Laboratories where he held positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago in 1998. In this position, he was in charge of Abbott’s pharmaceuticals business in the U.S. with responsibility for global pharmaceutical research and development.

 

Mr. Higgins has been a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins serves on the boards of Zimmer Biomet.

Arthur Higgins

Board Member

Mariano has been appointed to the Board of Directors in November 2018. He has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

He recently stepped down as CEO of GBT, a Latin-American biopharmaceutical company with presence in 10 countries.   At GBT, Mariano launched the company, established the strategy, steered the project through its successive acquisitions and transformations and finally took the company public.  During his career, Mariano worked with investment firms Aqua Capital, Warburg Pincus and Advent International.   He also held several operational positions at Bausch+Lomb in Sao Paulo, Pfizer in New York and in Sao Paulo, McKinsey in Madrid and Eli Lilly in Buenos Aires.

 

Mariano holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School, for which he earned a Fulbright scholarship.

Mariano Garcia-Valiño

Board Member

Joel joined moksha8 in December 2014 as CEO. He has over 39 years of experience in the pharmaceutical industry, most of it has been spent in Latin America; working for leading pharmaceutical companies such as Sanofi and UCB.

 

His most recent role, Joel was Interlatina regional manager for Sanofi, Latin America regional manager for UCB and CEO of Meizler UCB Brazil.

 

Joel brings extensive experience in leading highly successful teams, merging, acquiring, launching and marketing pharmaceutical products in Latin America, particularly in the CNS, Diabetes, Oncology and Respiratory therapeutic areas.

 

Joel Barlan

Chief Executive Officer

Board of Directors

Stig Pedersen is the Executive Chairman of moksha8 and an active investor and Board Member in many companies within the health, medical and biotechnology industry in Europe and North America. He also serves as an Advisor to the Lundbeck Foundation.

 

He joined Lundbeck in 1992 where he held a number of positions. He served as member of the Executive Board and an Executive Vice President of Commercial Operations from 2003 to 2011. From 2005 to 2011 he was also Chief Commercial Officer and responsible for Lundbeck´s global sales and marketing activities. From 1992 to 1998 he served as Director of Business Development, Director of Corporate Affairs, Managing Director of Lundbeck’s subsidiary in the Netherlands, respectively.

 

As Senior Vice President, Corporate Affairs, from 1998, he was responsible for the 3 product deals, transforming Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Mr. Pedersen took over Operations in the America’s, Asia and Africa.

 

Mr. Pedersen served as an Economist at Dansk Shell A/S from 1985 to 1986, and joined Ciba-Geigy in Denmark 1986-1989, as respectively, Market Manager, Project Manager and Member of the Divisional Management. He was appointed Assistant Region Head in Basel, Switzerland, at Ciba-Geigy AG in 1990.

 

He serves as the Chairman of the Board of Directors in Transmedica A/S, Microlytic ApS, Chemometec A/S and Nuevolution A/S. He is Member of the Board of Directors of MSI

Methylation Sciences Inc in Vancouver, Canada and of Index Pharmaceuticals AB in Stockholm, Sweden. Previously, he has served as Chairman of the Board of Directors in Tytex A/S, Ikast, Denmark, Vernal AG, Basle, Switzerland, and R5 A/S, Copenhagen, Denmark.

 

Stig Pedersen

Executive Chairman

Mr. Turner has 30 years of experience as an entrepreneur, operating manager and venture capitalist. In 1993, he founded a private investment company called Montreux Equity Partner where he is the Managing Director and General Partner.

 

He has been a member and Chairman of GC Aesthetics and he also serves on the Board of Directors of multiple companies including Epirus Biopharmaceuticals, Inc., Glaukos Corporation, Orexigen Therapeutics, Inc., Renal CarePartners, Inc., Transcept Pharmaceuticals, Inc. and Tobira Therapeutics, Inc. Mr. Turner holds a bachelor’s degree from California State University, Sacramento.

 

Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Previously, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals in 1997.

 

Previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Board of Trustees at Woodside Priory School and a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.

 

He started his career with Price Waterhouse in the high technology group.

 

Daniel Turner III

Board Member

Pascal Forget is a Senior Executive with 34 Years of experience as President, Managing Director and Area Manager in the pharmaceutical and agro-veterinarian industries, working for leading groups such as Schering Plough, Hoescht Roussel, Roussel Uclaf and Grupo Farma.

For the last 14 years, Mr. Forget has been the CEO of a highly successful international pharmaceutical group with full LATAM coverage.

 

With solid expertise in M&A and joint ventures within the Pharma industry and international experience as an operational and global business manager in Latin and Central America and Europe, Mr. Forget is a valuable addition to moksha8’s BoD.

 

Mr. Forget holds a CPA Degree and an MBA degree from Ottawa University.

Pascal Forget

Board Member

Mr. Higgins serves as President and Chief Executive Officer and Director of Depomed since March 2017. He is a highly respected executive with over 35 years’ experience in the pharmaceutical and healthcare industry. He has extensive leadership experience in the global healthcare market and has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area.

He served as a Senior Advisor to Blackstone Healthcare Partners where he focused on product-based healthcare acquisitions.

 

Before Blackstone, he served as Chairman of the Bayer HealthCare Executive Committee in July 2004 and Chairman of the Board of Management of Bayer HealthCare AG in January 2006. During his tenure at Bayer, Mr. Higgins led the restructuring and strengthening of Bayer HealthCare including the acquisition and integration of Schering AG and the over-the-counter medicines business of Roche.

 

Prior to joining Bayer, he was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, N.J. Higgins also spent 14 years with Abbott Laboratories where he held positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago in 1998. In this position, he was in charge of Abbott’s pharmaceuticals business in the U.S. with responsibility for global pharmaceutical research and development.

 

Mr. Higgins has been a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins serves on the boards of Zimmer Biomet.

Arthur Higgins

Board Member

Mariano has been appointed to the Board of Directors in November 2018. He has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

He recently stepped down as CEO of GBT, a Latin-American biopharmaceutical company with presence in 10 countries.   At GBT, Mariano launched the company, established the strategy, steered the project through its successive acquisitions and transformations and finally took the company public.  During his career, Mariano worked with investment firms Aqua Capital, Warburg Pincus and Advent International.   He also held several operational positions at Bausch+Lomb in Sao Paulo, Pfizer in New York and in Sao Paulo, McKinsey in Madrid and Eli Lilly in Buenos Aires.

 

Mariano holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School, for which he earned a Fulbright scholarship.

Mariano Garcia-Valiño

Board Member

Joel joined moksha8 in December 2014 as CEO. He has over 39 years of experience in the pharmaceutical industry, most of it has been spent in Latin America; working for leading pharmaceutical companies such as Sanofi and UCB.

 

His most recent role, Joel was Interlatina regional manager for Sanofi, Latin America regional manager for UCB and CEO of Meizler UCB Brazil.

 

Joel brings extensive experience in leading highly successful teams, merging, acquiring, launching and marketing pharmaceutical products in Latin America, particularly in the CNS, Diabetes, Oncology and Respiratory therapeutic areas.

 

Joel Barlan

Chief Executive Officer

Board of Directors

Stig Pedersen

Executive Chairman

Stig Pedersen is the Executive Chairman of moksha8 and an active investor and Board Member in many companies within the health, medical and biotechnology industry in Europe and North America. He also serves as an Advisor to the Lundbeck Foundation.

 

He joined Lundbeck in 1992 where he held a number of positions. He served as member of the Executive Board and an Executive Vice President of Commercial Operations from 2003 to 2011. From 2005 to 2011 he was also Chief Commercial Officer and responsible for Lundbeck´s global sales and marketing activities. From 1992 to 1998 he served as Director of Business Development, Director of Corporate Affairs, Managing Director of Lundbeck’s subsidiary in the Netherlands, respectively.

 

As Senior Vice President, Corporate Affairs, from 1998, he was responsible for the 3 product deals, transforming Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Mr. Pedersen took over Operations in the America’s, Asia and Africa.

 

Mr. Pedersen served as an Economist at Dansk Shell A/S from 1985 to 1986, and joined Ciba-Geigy in Denmark 1986-1989, as respectively, Market Manager, Project Manager and Member of the Divisional Management. He was appointed Assistant Region Head in Basel, Switzerland, at Ciba-Geigy AG in 1990.

 

He serves as the Chairman of the Board of Directors in Transmedica A/S, Microlytic ApS, Chemometec A/S and Nuevolution A/S. He is Member of the Board of Directors of MSI Methylation Sciences Inc in Vancouver, Canada and of Index Pharmaceuticals AB in Stockholm, Sweden. Previously, he has served as Chairman of the Board of Directors in Tytex A/S, Ikast, Denmark, Vernal AG, Basle, Switzerland, and R5 A/S, Copenhagen, Denmark.

 

Daniel Turner III

Board Member

Mr. Turner has 30 years of experience as an entrepreneur, operating manager and venture capitalist. In 1993, he founded a private investment company called Montreux Equity Partner where he is the Managing Director and General Partner.

 

He has been a member and Chairman of GC Aesthetics and he also serves on the Board of Directors of multiple companies including Epirus Biopharmaceuticals, Inc., Glaukos Corporation, Orexigen Therapeutics, Inc., Renal CarePartners, Inc., Transcept Pharmaceuticals, Inc. and Tobira Therapeutics, Inc. Mr. Turner holds a bachelor’s degree from California State University, Sacramento.

 

Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Previously, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals in 1997.

 

Previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Board of Trustees at Woodside Priory School and a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.

 

He started his career with Price Waterhouse in the high technology group.

 

Pascal Forget

Board Member

Pascal Forget is a Senior Executive with 34 Years of experience as President, Managing Director and Area Manager in the pharmaceutical and agro-veterinarian industries, working for leading groups such as Schering Plough, Hoescht Roussel, Roussel Uclaf and Grupo Farma.

 

For the last 14 years, Mr. Forget has been the CEO of a highly successful international pharmaceutical group with full LATAM coverage.

 

With solid expertise in M&A and joint ventures within the Pharma industry and international experience as an operational and global business manager in Latin and Central America and Europe, Mr. Forget is a valuable addition to moksha8’s BoD.

 

Mr. Forget holds a CPA Degree and an MBA degree from Ottawa University.

Arthur Higgins

Board Member

Mr. Higgins serves as President and Chief Executive Officer and Director of Depomed since March 2017. He is a highly respected executive with over 35 years’ experience in the pharmaceutical and healthcare industry. He has extensive leadership experience in the global healthcare market and has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area.

He served as a Senior Advisor to Blackstone Healthcare Partners where he focused on product-based healthcare acquisitions.

 

Before Blackstone, he served as Chairman of the Bayer HealthCare Executive Committee in July 2004 and Chairman of the Board of Management of Bayer HealthCare AG in January 2006. During his tenure at Bayer, Mr. Higgins led the restructuring and strengthening of Bayer HealthCare including the acquisition and integration of Schering AG and the over-the-counter medicines business of Roche.

 

Prior to joining Bayer, he was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, N.J. Higgins also spent 14 years with Abbott Laboratories where he held positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago in 1998. In this position, he was in charge of Abbott’s pharmaceuticals business in the U.S. with responsibility for global pharmaceutical research and development.

 

Mr. Higgins has been a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins serves on the boards of Zimmer Biomet.

Mariano Garcia-Valiño

Board Member

Mariano has been appointed to the Board of Directors in November 2018. He has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

He recently stepped down as CEO of GBT, a Latin-American biopharmaceutical company with presence in 10 countries.   At GBT, Mariano launched the company, established the strategy, steered the project through its successive acquisitions and transformations and finally took the company public.  During his career, Mariano worked with investment firms Aqua Capital, Warburg Pincus and Advent International.   He also held several operational positions at Bausch+Lomb in Sao Paulo, Pfizer in New York and in Sao Paulo, McKinsey in Madrid and Eli Lilly in Buenos Aires.

 

Mariano holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School, for which he earned a Fulbright scholarship.

Joel Barlan

Chief Executive Officer

Joel joined moksha8 in December 2014 as CEO. He has over 39 years of experience in the pharmaceutical industry, most of it has been spent in Latin America; working for leading pharmaceutical companies such as Sanofi and UCB.

 

His most recent role, Joel was Interlatina regional manager for Sanofi, Latin America regional manager for UCB and CEO of Meizler UCB Brazil.

 

Joel brings extensive experience in leading highly successful teams, merging, acquiring, launching and marketing pharmaceutical products in Latin America, particularly in the CNS, Diabetes, Oncology and Respiratory therapeutic areas.